U.S. News: Could gut microbes affect pancreatic cancer survival?

U.S. News and World Report highlighted recent research from the University of Cincinnati Cancer Center that found several enriched species associated with enhanced tumor immune response in the microbiomes of long-term pancreatic cancer survivors.

“Little information exists to help us understand why some patients are cured from pancreatic cancer and unfortunately most are not,” said Jordan Kharofa, MD, University of Cincinnati Cancer Center physician-researcher and associate professor in the UC College of Medicine’s Department of Radiation Oncology. “These species may help to promote immune response to pancreas cancer but this has not yet been proven.

“There is a growing understanding that the microbiome is a part of the normal immune response. The importance of the microbiome in response to immunotherapy drugs in melanoma and other cancer types is well established,” Kharofa continued. “For the first time we are seeing that similar species are enriched in patients cured from pancreas cancer. We’re excited to explore this further and to evaluate if modulating the microbiome can be a therapeutic avenue in these patients.”

Read more about the research.

Read the U.S. News and World Report story, originally published by HealthDay.

Read coverage of the research from Healio.

Featured photo at top of pancreatic cancer cell courtesy of the National Cancer Institute.

 

Related Stories

1

UC biologist talks about 'pearmageddon'

March 16, 2026

WLWT talks to UC biologist and Department Head Theresa Culley about invasive, nonnative Callery pear trees that are spreading across Ohio forests after they were introduced by landscapers more than 50 years ago.

3

Trial results support weekly buprenorphine treatment of opioid use disorder during pregnancy

March 16, 2026

Supported by the National Institutes of Health (NIH), researchers led by the University of Cincinnati's John Winhusen published clinical trial results in JAMA Internal Medicine that found administering weekly injectable extended-release buprenorphine for treatment of opioid use disorder during pregnancy led to higher rates of abstinence from illicit opioids than buprenorphine given daily under the tongue, one of the standard methods of treatment.